Manufacturing
Selling a specialty chemical or coatings company: formulas in diligence
By SourceX Editorial · Reviewed by Noah Loul ·
Short answer
When selling a specialty chemical or coatings company, disclose formulas in stages. Buyers see product-level summary records first, competitively sensitive detail goes to a clean team, and full formulas appear only late, in controlled form, to the few people who need them. Keeping that sequence helps preserve trade secret protection if the deal fails.
Key takeaways
- Formulas are usually protected as trade secrets, so how they are shown in diligence affects whether that protection survives a failed deal.
- Most buyers can value the business from summary records such as product families, specifications, customer approvals and batch yields.
- When the buyer is a competitor, a clean team should review pricing, margins and formulation detail and pass on only conclusions.
- Full formulas belong at confirmatory diligence or closing, shown view-only or in a supervised session, with every access logged.
- Buyers also test ownership: toll agreements, customer-funded development and employee agreements decide which formulas can transfer.
Why formulas need a disclosure plan before the data room opens#
Formulas need a disclosure plan because, in most specialty chemical and coatings businesses, they are protected as trade secrets rather than patents, and that protection depends on how the owner behaves. Under the Defend Trade Secrets Act, information qualifies as a trade secret only if the owner has taken reasonable measures to keep it secret and it has value from not being generally known.
A sale process tests those measures. If every first-round bidder can download the formula master, and one of them walks away and later launches a near-identical primer, the seller has to argue that broad disclosure was still reasonable. DOJ guidance lists the kinds of measures that count: need-to-know access, confidentiality agreements, telling employees what is secret, and keeping documents locked away.
A staged plan turns those measures into deal mechanics. This is general information, not legal advice; M&A counsel and, where the buyer is a competitor, antitrust counsel should set the protocol for your transaction.
What can a buyer learn without seeing a formula?#
A buyer can value most of a specialty chemical or coatings company from product-level summary records, without seeing a single formula. Buyers want to know what sells, to whom, how reliably it is made and how hard it would be for a customer to switch. None of that requires ingredient lists or loadings.
Prepare these summaries early and check that they reconcile with the financial statements. A gap between the product master and invoiced sales raises more questions in diligence than any formula would.
| Summary record | What it tells the buyer | Formula exposure |
|---|---|---|
| Product master by family and end market | Which lines drive sales and margin | None |
| Technical data sheets and safety data sheets | Published performance and hazard information | Low; already shared with customers |
| Customer approvals and specification listings | Where switching would force a customer to requalify | None |
| Batch yield, rework and adjustment summaries | How consistently products are made | Low when reported by product family |
| Raw material categories and single-source items | Supply risk and supplier concentration | Moderate; keep to categories, not grades and loadings |
| Regulatory status by product | Chemical inventory listings, VOC compliance and labeling duties | Low |
| Complaint and return history | Field performance and quality discipline | None |
A staged-disclosure checklist for formulas#
A staged-disclosure checklist assigns every formula-related document to the point in the process when a buyer actually needs it. Decide the stages before the data room opens, so a bidder's early request gets a consistent answer instead of a fresh negotiation.
Log every view in stages three and four. The access log is the record that shows reasonable measures if a failed bidder's product later looks familiar.
- Stage 1, teaser and confidential information memorandum: product families, end markets, plant capabilities and certifications, with no chemistry beyond what the website already says.
- Stage 2, first-round data room: the summary records above, published data sheets, regulatory status and customer approval lists.
- Stage 3, clean team room: customer-level pricing, margin by formula, raw material costs and R&D project detail, seen only by named clean team members who report conclusions rather than documents.
- Stage 4, confirmatory diligence after a letter of intent: a sample of formulas shown view-only or in a supervised session to the buyer's technical lead, or reviewed by an independent chemist who confirms they exist and match specifications.
- Stage 5, signing and closing: the full formula library, lab notebooks, batch records and process instructions transfer under the purchase agreement.
How a clean team handles formulas and pricing#
A clean team is a small, named group that reviews competitively sensitive information on the buyer's behalf and passes only aggregated findings to the deal team. When the buyer competes with you, the clean team is the main tool for keeping pricing, margins and formulation detail away from people who set prices or run product development.
Antitrust rules may limit what competitors exchange before closing, and those limits apply whether or not the deal completes. Counsel on both sides usually agree a clean team agreement that names members, lists the categories of information and sets what form the outputs take.
Clean team members are often outside consultants, outside counsel or buyer employees with no commercial role. Files are watermarked and view-only, downloads are disabled, and the seller's counsel reviews each clean team report before the buyer's deal team sees it. At the end, materials are returned or destroyed and the clean team confirms that in writing.
Which formulas does the company actually own?#
The company owns the formulas its employees developed under proper agreements, but many coatings and chemical businesses also hold formulas that belong to someone else. Buyers test this carefully, because a formula the seller cannot transfer is worth little to them.
Employee agreements deserve a specific look. Federal law requires employers to give notice of whistleblower immunity in employee contracts that govern trade secrets or confidential information, and agreements entered into or updated without it can limit the remedies available against that person. Counsel can confirm whether your forms need updating before the sale.
| Formula source | Usual owner | What buyers check |
|---|---|---|
| Developed in-house by employees | The company, where confidentiality and invention assignment agreements are in place | Signed agreements and the notebook trail |
| Developed with outside consultants | Depends on a written assignment | Consulting agreements and assignment language |
| Toll blended for a customer from its formula | Usually the customer | Toll agreement scope and return or destruction duties |
| Customer-funded development | Whatever the development agreement says | IP clauses, field-of-use limits and exclusivity |
| Licensed from a resin supplier or university | The licensor | License scope and change-of-control consent |
| Acquired with an earlier product line | The company, if the earlier purchase transferred it | Schedules from the prior asset purchase |
Illustrative example: a coatings maker sells to a competitor#
Illustrative: a fictional family-owned maker of industrial floor and tank-lining coatings receives an offer from a larger competitor. Its formulas sit in a formulation spreadsheet kept by the lab director and in older paper notebooks, while batch tickets and QC results live in its ERP.
The owners open the first-round room with product family summaries, customer approvals and published data sheets only. A clean team of outside consultants reviews margins by product family and raw material dependencies. After the letter of intent, the buyer's technical director sees a sample of formulas in a supervised session, with no copies taken. Formulas the company blends for one customer under a toll agreement are excluded entirely.
A second bidder drops out after the first round, having seen no formulas. The deal closes with the formula library transferring at closing, and the access log goes into the closing set as part of the buyer's own trade secret record.
Where formulation records fit if you also license data#
Formulation records, meaning formulas linked to test results and batch outcomes, may interest AI developers building materials and formulation models, separately from any sale of the company. Any license granted before a sale becomes a diligence item: buyers will read its scope, exclusivity, term and what was actually delivered.
SourceX runs these licenses through the SourceX five-step transaction: Supply, Rights, Preparation, Approval and Delivery. Nothing is shared during the initial assessment, which collects metadata only, the supplier approves each step, and commercial formulas can be excluded or abstracted to ingredient classes. The SourceX Evidence Packet records provenance, licensing rights, permitted use, the privacy record and release authorization, the same kind of record a buyer's counsel asks to see.
Frequently asked questions
Should a buyer ever see full formulas before signing?
Some buyers insist, especially when one product line drives most of the value. Common compromises are a supervised viewing for the buyer's technical lead, formulas redacted to ingredient classes, or an independent chemist who confirms the formulas exist and match specifications without reporting their contents. The right choice depends on the buyer, the deal stage and counsel's advice.
Is the process different when the buyer is a private equity firm?
Usually lighter, because a financial buyer rarely competes directly. Check its portfolio first: if it owns a coatings or chemical business, treat that company as a competitor for clean team purposes. Staged disclosure still protects you if the deal fails, so keep the sequence and widen access sooner only where counsel agrees.
Do patents change how formulas are handled in diligence?
Partly. A patented formulation is already public in the patent, so diligence focuses on claim scope, validity, ownership and freedom to operate. The unpatented know-how around it, such as process conditions, raw material grades and batch adjustments, usually remains a trade secret and follows the staged approach.
What happens to lab notebooks in the sale?
Lab notebooks normally transfer with the business as part of its records and know-how. Buyers ask whether they are paper, scanned or held in an electronic lab notebook, and whether formulas can be traced to test results. Digitized, linked formulation history is easier to review in diligence and easier to integrate after closing.
Can a failed bidder use what it learned?
The confidentiality agreement should restrict use to evaluating the deal and require return or destruction of materials. Enforcing it depends on showing what was disclosed and to whom, which is why staged access, watermarking and the access log matter as much as the agreement itself.
Sources
- Under 18 U.S.C. 1839(3), information qualifies as a trade secret only if the owner has taken reasonable measures to keep it secret and it derives independent economic value from not being generally known. Source
- DOJ guidance states protective measures must be reasonable under the circumstances, citing need-to-know access, confidentiality agreements, advising employees and keeping documents locked. Source
- 18 U.S.C. 1833(b) requires employers to give notice of whistleblower immunity in any contract with an employee governing use of trade secrets or confidential information. Source
- An employer that fails to provide the 1833(b) immunity notice may not recover exemplary damages or attorney fees against an employee who did not receive it, for contracts entered into or updated after enactment. Source
Related resources
- SolutionData monetization: earning revenue from data you already have
- IndustryHealthcare administration data
- QuestionDo AI companies buy private business data?
- QuestionData licensing vs data selling: what's the difference?
- InsightHow to monetize your business data: a practical guide
- InsightGDPR and selling data to AI companies
See if your company qualifies
A short company assessment. No data uploads are needed.